ResearcherUniversity of California, Los AngelesActive in the last 2 years
Soichiro Ako
Matched on OpenAlex author ID A5064651865. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1111/cas.70533↗
- Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
- Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000001790↗
- Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Co-author DOI 10.1007/s10620-019-06006-6↗
- Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2019.1638685↗
- Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Co-author DOI 10.1016/j.pan.2016.12.011↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shigeru Horiguchi · 5 shared papers, 2017–2026 · strength 0.57
- Paper Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/cas.70533↗
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Daisuke Uchida · 5 shared papers, 2017–2026 · strength 0.57
- Paper Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/cas.70533↗
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Hideaki Kinugasa · 5 shared papers, 2017–2026 · strength 0.57
- Paper Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/cas.70533↗
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Hiroyuki Terasawa · 3 shared papers, 2019–2026 · strength 0.41
- Paper Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/cas.70533↗
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. DOI 10.1080/15384047.2019.1638685↗
- Kazuhiro Nouso · 4 shared papers, 2017–2021 · strength 0.35
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Paper Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. DOI 10.1080/15384047.2019.1638685↗
- Kazuyuki Matsumoto · 4 shared papers, 2017–2021 · strength 0.35
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Paper Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. DOI 10.1080/15384047.2019.1638685↗
- Hironari Kato · 4 shared papers, 2017–2021 · strength 0.35
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Paper Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. DOI 10.1080/15384047.2019.1638685↗
- Koichiro Tsutsumi · 2 shared papers, 2017–2026 · strength 0.28
- Shinichiro Muro · 3 shared papers, 2017–2021 · strength 0.26
- Paper Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. DOI 10.1080/15384047.2021.1980312↗
- Paper Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-G… DOI 10.1007/s10620-019-06006-6↗
- Paper Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. DOI 10.1016/j.pan.2016.12.011↗
- Kazuya Yasui · 1 shared paper, 2026 · strength 0.22
- Tatsuya Kikuchi · 1 shared paper, 2026 · strength 0.22
- Yuki Fujii · 1 shared paper, 2026 · strength 0.22
- Kosei Takagi · 1 shared paper, 2026 · strength 0.22
- Motoyuki Otsuka · 1 shared paper, 2026 · strength 0.22
- Hiroyuki Okada · 2 shared papers, 2019–2020 · strength 0.19
- Yaroslav Teper · 1 shared paper, 2021 · strength 0.15
- Linda Ye · 1 shared paper, 2021 · strength 0.15
- Roxanne L. Massoumi · 1 shared paper, 2021 · strength 0.15
- Guido Eibl · 1 shared paper, 2021 · strength 0.15
- Oscar Joe Hines · 1 shared paper, 2021 · strength 0.15
- Yuzo Umeda · 1 shared paper, 2021 · strength 0.10
- Ryuichi Yoshida · 1 shared paper, 2021 · strength 0.10
- Hiroyuki Okada · 1 shared paper, 2021 · strength 0.10
- Hiroyuki M. OKADA · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.